Global Diabetes Rates to Catapult to 552 Million by 2030
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 07/25/12 -- TriMarkPublications.com cites in its newly published ", Metabolic Syndrome and Cardiovascular Disease" report that global rates will catapult to 552 million by 2030. For more information, visit: .
can be categorized into two main modalities: Type I , i.e., juvenile onset , and Type II , i.e., adult onset . The vast majority of incidences of are Type II , which is strongly linked to health problems such as cardiovascular disease (CVD), obesity, decreased renal function, deterioration of vision and neuropathy. The global market for oral anti-diabetics and human insulins will nearly double over the next ten years, reaching close to $70 billion by 2020.
The ", Metabolic Syndrome and Cardiovascular Disease" report covers:
Mellitus
Metabolic Syndrome
Stress-Induced Hyperglycemia
Anti-Hypertensive Drugs
Cholesterol Management Drugs
Anticoagulants
Sulfonylureas
Meglitinides
Biguanides
Thiazolidinediones (TZDs)
The ", Metabolic Syndrome and Cardiovascular Disease" report examines companies manufacturing equipment and supplies in the world. Companies covered include: A. Menarini, Abbott, Amgen, AstraZeneca, Bayer, BodyMedia, Cybermedical, Debiotech, DexCom, Echo, Eksigent, Eli Lilly, Elixir, Flamel, GlaxoSmithKline, Insulet, iSense, Isis, Johnson & Johnson, KYORIN, M-Biotech, Medtronic, Merck, Merck KGaA, MicroIslet, Mitsubishi Tanabe, Nipro, Novartis, Novo Nordisk, Novocell, ONO, Orexigen, Pfizer, Roche, Sanofi-Aventis, Sensors for Medicine and Science, Siemens, Smiths, SOOIL, Takeda, TheraFuse, U.S. Diagnostics, VeraLight, Vivus and Ypsomed.
Detailed charts with sales forecasts and marketshare data are included. For more information, visit: .
TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit .
The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.
TriMarkPublications.com
Media Relations
1-888-OK-TRIMARK
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.07.2012 - 17:45 Uhr
Sprache: Deutsch
News-ID 168695
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Health & Nutrition
Diese Pressemitteilung wurde bisher 228 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Global Diabetes Rates to Catapult to 552 Million by 2030"
steht unter der journalistisch-redaktionellen Verantwortung von
TriMarkPublications.com (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
